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Summary  51 
Objective: The short synacthen test (SST) is widely used to assess patients for adrenal 52 
insufficiency but the frequency and protocols used across different centres for the low-53 
dose test (LDT) are unknown. This study aimed to survey centres and test the accuracy 54 
of ten different synacthen preparation strategies used for the LDT. 55 
Methods: Members of six international endocrine societies were surveyed regarding 56 
diagnostic tests used for adrenal insufficiency, and in particular the SST. Synacthen was 57 
diluted for the LDT and concentrations measured using a synacthen ELISA.  58 
Results: Survey responses were received from 766 individuals across 60 countries (52% 59 
adult, 45% paediatric endocrinologists). The SST is used by 98% of centres: 92% using 60 
high-dose (250 µg), 43% low-dose, and 37% both. Ten low-dose dilution methods were 61 
assessed and variation in synacthen concentration was demonstrated with intra-method 62 
coefficients of variation (CV) ranging from 2.1% to 109%. The method using 5% 63 
dextrose as a diluent was the least variable (CV of 2.1%). The variation in dilution 64 
methods means that the dose of synacthen administered in a LDT may vary between 65 
0.16 µg and 0.81 µg.  66 
Conclusions: The high-dose SST is the most popular diagnostic test of adrenal 67 
insufficiency but up to 72% of paediatric endocrinologists use a LDT. There is 68 
considerable variation observed both within and between low-dose synacthen dilution 69 
methods creating considerable risk of inaccurate dosing and thereby invalid results.  70 
5 
INTRODUCTION  71 
The use of the ACTH-stimulation test, or short synacthen test (SST), has been growing 72 
in popularity,1,2 and is the most widely used investigation of adrenocortical function in 73 
some countries.3 It is being considered increasingly as WKH³VWDQGDUG´IRUWKHGLDJQRVLV74 
of adrenal insufficiency.4-6 The SST mimics the ACTH stimulus to the adrenal cortex 75 
and involves administration of either high-dose supra-physiological 250 µg or low-dose 76 
physiological, usually 1 µg, synacthen. Both the high and low-dose tests are used in 77 
clinical practice and results of meta-analyses do not show significant superiority of one 78 
test over the other.7-11 Worldwide clinician preference for adrenal function testing and 79 
the popularity of the high and low dose SST are unknown. We report the results of an 80 
international survey, of both paediatric and adult endocrinologists, to assess current 81 
practice.  82 
One form of diagnostic-grade synacthen is commercially available, 83 
manufactured in 250 µg/mL ampoules, necessitating large dilutions if administration of 84 
a low-dose is required. A British survey of paediatric endocrinologists in 2012 reported 85 
that, amongst the 82% of respondents who use the low-dose test, 14 different dilution 86 
methods were used.3 These varied in the amount of synacthen utilised for the initial 87 
dilution (0.1 mL to 1 mL), the volume of the diluent (10 mL to 1 litre), the diluent type 88 
(5% dextrose and 0.9% saline), and the number of dilution steps (one, two, or three) 89 
employed to prepare the required concentration.3  90 
There is a paucity of literature on the accuracy or reproducibility of making up 91 
low-dose synacthen. The majority of related work pertains to the analysis of adsorptive 92 
losses on glass and plastic equipment during the dilution process, with losses 93 
proportionate to the length of the plastic device used for administration.12-14 We 94 
addressed this important clinical issue in an in vitro study and report the accuracy and 95 
6 
reliability of making up 1 µg doses of synacthen by ten of the different methods 96 
currently in use.  97 
7 
MATERIALS AND METHODS 98 
International survey 99 
A thirteen-question online survey (Supporting Information) was distributed to the 100 
members of six endocrine learned societies with a total of 6744 members: the USA 101 
based Pediatric Endocrine Society (PES, n = 1381), the UK based Society for 102 
Endocrinology (SfE, n = 1188), European Society of Endocrinology (ESE, n = 1540), 103 
European Society for Paediatric Endocrinology (ESPE, n =1239), The Endocrine 104 
Society of Australia (ESA, n = 1100), and the Australasian Paediatric Endocrine Group 105 
(APEG, n = 296). The survey sought to ascertain: the popularity of various diagnostic 106 
tests for adrenal insufficiency; the indications for choosing the low-dose (LDT) or high-107 
dose (HDT) SST in preference to the other; LDT dose, administration route of 108 
synacthen, cortisol sampling times and cortisol thresholds for test interpretation.  109 
Survey invitations were sent via the e-mailing list or communications bulletin of 110 
the societies between March 2016 and January 2017. A follow-up reminder was sent 111 
after the initial email. Respondents were given the choice of completing the survey using 112 
an online surveying platform (https://surveyplanet.com) or an emailed Microsoft 113 
:RUGGRFXPHQW0LQRUFKDQJHVZHUHPDGe to the survey in order to meet the various 114 
stipulations of the societies.  115 
 116 
Low-dose synacthen dilution study 117 
Results from the 2012 survey of British paediatric endocrinologists were used to 118 
investigate precision and accuracy of the ten most commonly employed dilution 119 
methods for making up 1 µg low-dose synacthen (Table 1).3 Each dilution protocol was 120 
followed and the resultant solution made up five times in order to evaluate intra-method 121 
variability. In the nine methods yielding a sufficient final solution, three 1 mL samples 122 
were taken (from the top, middle and bottom of the bag of diluent or the syringe) to 123 
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assess any variation that may be caused by insufficient mixing. Samples were extracted 124 
from the superior quarter of the sample bag/final mL of the syringe (top samples), the 125 
vertical halfway point of the sample bag/middle mL of the syringe (middle samples), or 126 
taken from the sample bag port/first mL ejected from the sample syringe (bottom 127 
samples). All samples were prepared on a single day, by one of three investigators, with 128 
each method made up by the same investigator. 129 
Medical ward equipment (syringes, fluid bags, needles) was used in preference 130 
to laboratory equipment to simulate clinical conditions. The 1 mL synacthen ampoules 131 
containing 250 µg/mL (Mallinckrodt Pharmaceuticals, Dublin, Ireland) were all from 132 
the same manufacturing batch. Synacthen is an inherently unstable drug, rapidly 133 
degrading in natural light and at room temperature; therefore ampoules were refrigerated 134 
until use.12,14 New needles were used for each dilution step to avoid cross contamination 135 
with more concentrated samples. Syringes were re-flushed three times when injecting 136 
into bags of diluent. Mixing was performed by slowly inverting the sample bag or the 137 
syringe five times, replicating typical ward-based practice. All samples containing the 138 
required final concentration of synacthen were frozen immediately at -80°C. 139 
 140 
Synacthen ELISA 141 
Synacthen concentrations were estimated using an ELISA format. Unless otherwise 142 
stated, all reagents were from Sigma-Aldrich (Poole, UK). NUNC MaxiSorpKLJK143 
protein-binding capacity 96-well ELISA plates (ThermoFisher Scientific Inc., Waltham, 144 
MA, USA) were coated with anti-ACTH mouse monoclonal antibody A1A12 (which 145 
recognises ACTH 1-24) at 2.5 µg/mL in coating buffer (103 mM sodium chloride; 41 146 
mM di-potassium hydrogen phosphate; 8.75 mM potassium dihydrogen phosphate; pH 147 
7.4). Standards were prepared in 0.9% saline at 0-10,000 pg/mL using solid synacthen 148 
(Bachem, Bubendorf, Switzerland). Samples containing synacthen were diluted in 0.9% 149 
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saline to a concentration that was within the standard linear dynamic range (1000-7500 150 
pg/mL) of the ELISA. To assess any variation or reduction in synacthen dose resulting 151 
from the laboratory dilutions necessary for the ELISA quantification, two vials of 152 
synacthen (250 µg/mL) were diluted as required and analysed in the ELISA. 153 
A 100 µL aliquot of sample diluent (phosphate-buffered saline, pH 7.4; 4% 154 
bovine serum albumin; 0.05% Tween 20) was added to each well followed by 100 µL 155 
of synacthen standard or test sample in duplicate. Plates were incubated at room 156 
temperature for 10 min, and then washed three times with washing buffer (150 mM 157 
sodium chloride; 8.5 mM di-potassium hydrogen phosphate; 1.75 mM potassium 158 
dihydrogen phosphate; 0.025% Tween 20; 0.0125% ProClin 300; pH 7.0). A 200 µL (1 159 
ug/mL) aliquot of anti-ACTH (7-23) antibody conjugated to HRP (Bioss Antibodies, 160 
Woburn, MA, USA) was applied to each well, and plates incubated for 30 minutes at 161 
room temperature. Subsequent to washing three times, 200 µL of 3,3',5·5'-162 
tetramethylbenzidine substrate reagent (Europa Bioproducts Ltd., Cambridge, UK) were 163 
added to each well. Following incubation at room temperature for 45 min the reaction 164 
was stopped by the addition of 100 µL of 0.5 M hydrochloric acid. A Labtech LT4500 165 
spectrophotometer (Labtech International Ltd., Uckfield, UK) was used to read 166 
absorption of the wells at 450 nm. Synacthen concentrations (pg/mL) were estimated 167 
from standard curves and corrected by the appropriate dilution factor (50-1000 times) 168 
to give the expected concentration in the synacthen solution used to deliver a 1 µg dose 169 
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(Table 1). All samples were assayed four to six times and the mean synacthen 170 
concentration determined. 171 
The intra-assay coefficient of variation (CV) was 1.70% at 2500 pg/mL, 1.69% 172 
at 5000 pg/mL, and 2.35% at 7500 pg/mL. The inter-assay CV was 4.54% at 5000 173 
pg/mL.  174 
 175 
Statistical analyses  176 
Summary statistics of frequency (%) and mean were used to analyse survey data. Free 177 
text responses detailing the clinical scenarios in which the HDT or LDT were used were 178 
categorised into themes using content analysis. For each of the ten dilution methods 179 
studied in the low-dose synacthen dilution analysis, intra-method and intra-bag/syringe 180 
variance was calculated and expressed as mean, SD and CV. Method 7 was excluded 181 
from intra-bag/syringe variance calculations due to an insufficient final volume. 182 
Unpaired t-WHVWVZLWK:HOFK¶VFRUUHFWLRQZHUHHPSOR\HGWRFRPSDUHFRPSRQHQWVRIWKH183 
different methods, including number of dilution steps, volume of diluent, and initial 184 
volume of synacthen used. A threshold of ± 10% (0.9 to 1.1 µg) was chosen as the 185 
acceptable range for deliverable synacthen dose values to fall within, reflecting standard 186 
laboratory practice.   187 
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RESULTS  188 
International survey  189 
Responses were received from 766 society members (11% overall response rate), 190 
working in 60 countries (single response received from 19 countries). Response rates 191 
varied between the societies: PES, 21% (n = 290), SfE, 19% (n = 220), ESE, 13% (n = 192 
220), ESPE, 3% (n = 36), ESA, < 1% (n = 7), and APEG, 4% (n = 13). Responses were 193 
received from clinicians working in the USA (36%), UK (29%), mainland Europe 194 
(25%), North America (excluding the USA) (4%), Asia (3%), Australasia (3%), Africa 195 
(< 1%), and South America (< 1%). Endocrinologists who worked mainly or entirely 196 
with adults made up 52% of respondents and 45% worked mainly or entirely with 197 
children and/or adolescents (97% of USA respondents). The remaining 3% of 198 
respondents either did not indicate their patient base or were not clinicians. 199 
 The SST was the most popular test for assessing adrenal insufficiency (Table 2). 200 
It was used by 98% overall with 92% using the HDT, 43% the LDT, and 37% both. The 201 
LDT was considerably more popular amongst paediatric endocrinologists (72%) 202 
compared with adult endocrinologists (17%). There was variation of LDT utility 203 
amongst respondents from different geographical regions: 76% of all respondents 204 
working in the USA used the LDT, 50% from the Middle East, 34% from mainland 205 
European countries, 30% from Australasia and 6% from the UK (82% UK paediatric 206 
endocrinologists in 2012 survey, not resurveyed). The most commonly utilised LDT 207 
dose was 1 µg (86% of question respondents) and an intermediate dose (between 5 µg 208 
and 15 µg) was used by 8%. Body surface area based doses (0.1 µg/m2 to 1 µg/m2) were 209 
used by 5%, 2% used weight-based calculations.  210 
Respondents stated their rationale for using the HDT or LDT: the most popular 211 
reasons for using the HDT were diagnosis of primary adrenal insufficiency and 212 
congenital adrenal hyperplasia, or because it was standard procedure. The LDT was 213 
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preferred to investigate secondary adrenal insufficiency. The majority administer the 214 
HDT by the intravenous route (81%), with 37% and 5% using intramuscular and 215 
subcutaneous routes, respectively. 216 
Thirty different combinations of cortisol sampling times were specified for the 217 
HDT and 37 for the LDT (Fig. 1). The most common times to sample were at 0, 30 and 218 
60 minutes (HDT 46%, LDT 51%), while 17% of LDT respondents utilised a 20-minute 219 
sample in their protocol. The most commonly used interpretive threshold for adequacy 220 
of adrenal function D³SDVV´ZDV! 500 nmol/L, used in 48% of HDT and 61% of LDT. 221 
More HDT users (27%) than LDT users (11%) utilised the higher threshold of > 550 222 
nmol/L. Similar proportions used thresholds below 500 nmol/L: HDT, 21% (range 374 223 
to 475 nmol/L), and LDT, 25% (range 380 to 495 nmol/L). 224 
 Serum cortisol levels without stimulation were used in the diagnosis of adrenal 225 
insufficiency by 76% (Table 2). When asked to specify further (n = 290), 92% used 226 
morning serum cortisol and 19% random cortisol sampling. Paired ACTH and serum 227 
cortisol sampling was used by 71% of all respondents. Less popular tests included the 228 
insulin tolerance test (used by 36% of respondents: adult, 54%; paediatric 15%), 229 
glucagon stimulation test (27%), metyrapone test (4%), clonidine stimulation test (3%), 230 
corticotrophin releasing hormone test (2%), and depot (prolonged) synacthen test (1%).  231 
 232 
Low-dose synacthen dilution study  233 
For eight of the ten different dilution strategies, a marked intra-method variability of the 234 
final synacthen concentration was observed, with CVs of over 10% (Table 1). The least 235 
variable was method 6, with a CV of 2.1%; the most variable was method 10, with a CV 236 
of 109%. Optimal dilution would have yielded synacthen concentrations able to deliver 237 
a dose close to 1 µg (acceptable range, 0.9 to 1.1 µg). However, the method means 238 
ranged from 0.16 µg (least accurate) to 0.81 µg (most accurate) (Table 1). The methods 239 
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bearing results closest to the range chosen as acceptable were 1, 4, and 6 (Fig. 2). Three 240 
methods (7, 9 and 10) had a mean concentration of less than half the expected dose 241 
ranging from 0.16 to 0.36 µg (Fig. 2), reflecting substantial losses of synacthen. To 242 
assess any variation or reduction in synacthen dose resulting from the laboratory 243 
dilutions necessary for the ELISA quantification, two vials of synacthen (250 µg/mL) 244 
were diluted and samples run over 23 assays. This yielded results of 247 ± 11 µg/mL 245 
and 223 ± 12 µg/mL, and indicated that the wide variation in deliverable dose detected 246 
in samples was not due to inaccuracies in the required laboratory dilutions. 247 
Intra-bag/syringe variability was high but unpredictable, with no part of the 248 
bag/syringe tending towards higher concentrated samples than another. Overall, top 249 
samples (n = 45) had a mean ± SD deliverable dose of 0.593 ± 0.298 µg synacthen, CV 250 
of 50.2%, middle samples (n = 45) 0.545 ± 0.286 µg, 52.5%, and bottom samples (n = 251 
45) 0.573 ± 0.293 µg, 51.3%. 252 
Method 6 was the only one to use 5% dextrose as a diluent and was the least 253 
variable method (CV of 2.1%) and most accurate, with means closest to the desired 1 254 
µg (0.79 to 0.84 µg). Six methods (n = 90 samples) involved a single dilution step, and 255 
together had a mean synacthen deliverable dose of 0.547 ± 0.319 µg, whilst four 256 
methods (n = 50) used double dilutions with an overall mean of 0.583 ± 0.24 µg (P = 257 
0.46; 95% confidence interval (CI): -0.058 to 0.131 µg). When comparing the different 258 
initial volumes of the 1 mL ampoule of 250 µg/mL synacthen used for dilution, six 259 
methods (n = 90) used all 1 mL and resulted in a mean synacthen deliverable dose of 260 
0.668 ± 0.212 µg. The remaining four methods (n = 50) used 0.5 mL or less and had a 261 
mean synacthen deliverable dose of 0.365 ± 0.318 µg (P < 0.0001; 95% CI: -0.404 to -262 
0.204 µg). A bag of diluent, rather than a syringe, was utilised in eight of the methods 263 
(n = 120), four of which (n = 60) used a large YROXPHRIGLOXHQW 250 mL, and had a 264 
mean synacthen deliverable dose of 0.572 ± 0.314 µg, and four methods (n = 60) used 265 
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a small volume of diluent, 50 mL, yielding a mean synacthen deliverable dose of 0.584 266 
± 0.283 µg (P = 0.837; 95% CI: -0.097 to 0.119 µg).  267 
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DISCUSSION  268 
This is the largest international survey of diagnostic tests for adrenal insufficiency to 269 
date. Although the response rate of 11% was low, this was a survey of society members 270 
some of whom are not in clinical practice and the response rate is in keeping with similar 271 
internet surveys.15-16 There was geographical variations in responses. Not all endocrine 272 
societies approached distributed the survey and this has contributed to the imbalance in 273 
paediatric and adult endocrinologist responses from certain regions. 274 
The SST was the most popular test for assessing HPA axis function and has been 275 
growing in popularity amongst endocrinologists, increasing from 24% in 1988,1 69% in 276 
1993,2 59% in 2005,17 to 98% in this survey and 100% of paediatric endocrinology 277 
centres in the UK in 2012.3 It is regarded now DV WKH ³VWDQGDUG´ WHVW IRU DGUHQDO278 
insufficiency.4 This is the first international survey to distinguish proponents of the HDT 279 
from the LDT. Whilst the HDT is used by 92% of respondents, and is the test of choice 280 
for diagnosing primary adrenal insufficiency, the LDT is used by 43%. Similar 281 
proportions of survey respondents practised as adult and paediatric endocrinologists. 282 
The LDT is popular amongst paediatric endocrinologists, 72% compared with 17% of 283 
adult endocrinologists, resonating the results of the British Society for Paediatric 284 
Endocrinology and Diabetes (BSPED) survey, where 82% used the LDT.3 This may 285 
reflect respiratory guidelines, which recommend the LDT for assessment of adrenal 286 
function in children on inhaled corticosteroids.18,19  287 
The sampling times and diagnostic cut-offs practised by the majority of 288 
respondents were in keeping with Endocrine Society guidelines,4 which state a peak 289 
cortisol less than 500 nmol/L at 30 or 60 min indicates adrenal insufficiency. Deviations 290 
from these guidelines were seen in 52% of HDT and 39% LDT users for cut-off and < 291 
1% HDT and 5% LDT users for timing. The tendency to employ lower diagnostic 292 
thresholds for serum cortisol is likely reflect a change in practice to locally derived cut-293 
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offs, dependent on the assay platform used. Additionally clinicians review the SST 294 
results in the context of the clinical suspicion of adrenal insufficiency.20,21 295 
Responses were received from people working in 60 countries and six 296 
continents, demonstrating a range of practises, resource settings and patient populations. 297 
There was a preponderance of responses from endocrinologists working in Europe and 298 
the USA; therefore the survey may not be truly representative of worldwide practice. 299 
Additionally, national practice cannot be assumed in the 136 countries with no 300 
respondent and 19 countries with a single respondent.  301 
This study has shown a high inter-method variability between different 302 
commonly employed dilution strategies for the low-dose SST. The variation in dose was 303 
from 0.16 µg to 0.81 µg when the dose should be 1 µg, thereby in all cases the dilution 304 
methods used provide inadequate dosing, with doses up to seven-fold less than required. 305 
There was variation when the same method was used to make up the 1 µg dose five 306 
times (intra-method variability) and variation when individual samples from the same 307 
final solution were compared (intra-bag/syringe variability), inferring inadequate 308 
mixing. This inaccuracy in dosing and variability between and within dilution methods 309 
may result in false positive synacthen tests with potentially important clinical sequelae.  310 
When similar methods (e.g., volume of diluent, proportion of synacthen ampoule 311 
used, number of dilution steps) were grouped and compared only the initial volume of 312 
synacthen was shown to significantly affect the final concentration: dilution methods 313 
using the full ampoule gave significantly higher concentrations and closer to the desired 314 
concentration. The most accurate and least variable method was the only one to use 5% 315 
dextrose, suggesting that dextrose may be the most suitable diluent for making up low 316 
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dose synacthen. However, this would require further investigation along with other 317 
possible diluents for synacthen. 318 
The plateau of the synacthen/cortisol dose response curve is thought to begin at 319 
approximately 5 µg of synacthen.12 The lowest dose of synacthen to maximally 320 
stimulate the adrenal gland has been found to be between 0.5 µg and 1 µg.12,22-25 The 321 
supra-physiological dose of 250 µg of synacthen employed by the HDT means that even 322 
marked variation in the actual dose delivered to the patient is unlikely to manifest 323 
clinically. However, the doses employed in the LDT are much closer to the amounts 324 
needed to produce a maximal adrenal response and thus, small variations in the 325 
administered dose, may have clinical ramifications, with the potential of false positive 326 
diagnoses of adrenal insufficiency. Using the results of this study, a patient undergoing 327 
a 1 µg LDT, using dilution methods 7, 9 or 10, may receive between 0.16 µg and 0.36 328 
µg of synacthen. These three methods used half or less of the synacthen ampoule, with 329 
methods 7 and 9 using 0.2 mL or less, a volume too small to draw up accurately using 330 
1 mL ward syringes.  331 
Intra-bag/syringe variability was high but similar between different parts (top, 332 
middle, bottom), suggesting mixing inadequacy but no specific area the synacthen 333 
settled in. In laboratory practice, mixing of constituents similar to those used in this 334 
study may take place over many hours with the use of specialised equipment, to be 335 
assured of uniform distribution throughout the diluent. 336 
7KHUHLVQR³VWDQGDUG´ZD\WRPDNHXSWKH µg synacthen dose. The method of 337 
adding 250 µg/mL to 250 mL of 0.9% saline (method 3), described by Dickstein et al12 338 
on introducing the 1 µg test in 1991, was later recommended by the meta-analysis of 339 
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Kazlauskaite and colleagues,8 but was neither the most popular method in the 2012 340 
British survey3 nor the most accurate method in the current study.  341 
Other sources of variation have been considered. These include potential losses 342 
caused by the adherence of synacthen to plastic, reported to be between 21.6 and 58.6% 343 
and proportional to the length of the device.13,14 This study made up low-dose synacthen 344 
under replicated ward conditions, using plastic syringes. Additional plastic laboratory 345 
equipment was used in the dilutions prior to ELISA analysis, potentially adding to the 346 
ORVVHV+RZHYHUWKH³FRQWURO´VDPSOHVGLOuted from a vial of synacthen with laboratory 347 
equipment showed very little variation and only minimal losses. Pharmaceutical 348 
industry standards require that an ampoule of 250 µg/ml synacthen contains between 95 349 
and 105% of the declared content, 237.5 µg and 262.5 µg, respectively (Mallinckrodt 350 
Pharmaceuticals, Dublin, Ireland) and this variation may be amplified when diluting the 351 
synacthen to physiological doses.  352 
Ward, rather than specialised, calibrated laboratory equipment was used for 353 
simulation purposes, reflecting current clinical practice, but other variables were 354 
controlled as far as possible. The synacthen was kept refrigerated until the point of use 355 
and a single investigator performed all dilutions for each individual method. The 356 
additional dilutions required to run the samples on the ELISA were performed under 357 
strict laboratory conditions and by a single investigator. In the reality of a less controlled, 358 
busy clinical environment ambient temperatures may vary, synacthen may degrade in 359 
sunlight or if left out of the refrigerator and many different personnel may perform the 360 
dilutions, all potentially increasing the inaccuracy of dilution and variability further. A 361 
systematic review has shown pre-prepared syringes for intravenous medication can 362 
reduce errors in the preparation and administration by 21%.26  363 
Our international survey showed the synacthen test is employed by 98% of 364 
endocrinologists, with 43% using the LDT. Our dilution study demonstrated 365 
19 
considerable variation and inaccuracy when preparing the low-dose of synacthen. The 366 
least variable methods were 1, 4 and 6 (Table 1). Although method 6 used 5% dextrose, 367 
the effect of diluent needs to be investigated further before any recommendations can 368 
be made. In addition, it would be expected that controlled laboratory/pharmacy 369 
conditions would impact positively on the accuracy of the delivered dose. 370 
371 
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FIGURE LEGENDS 
 
FIGURE 1 Chosen cortisol sampling times for respondents using high-dose and low-
dose synacthen tests. Each bar represents the percentage of respondents (HDT, n = 716, 
and LDT, n = 284) who measure cortisol levels at the times provided. For clarity, not 
all combinations of timings have been included in the graph (HDT, n = 30 different 
combinations and, LDT, n = 37). HDT, high-dose test; LDT, low-dose test. 
 
FIGURE 2 Accuracy and variability of 1 µg low-dose synacthen dilution methods. For 
each method tested, except method 7, each individual point indicates the mean 
deliverable amount of synacthen as calculated from three samples taken from the final 
bag/syringe dilution. For method 7, each individual point relates to a single sample 
measurement. Each method mean was calculated from five separate dilution 
experiments and is depicted by a short black line. The unbroken line at 1 µg represents 
the expected amount of synacthen administered if dilutions were optimal. The broken 
lines represent the upper (1.1 µg) and lower (0.9 µg) limits of the accepted range of 
dose variability of ± 10%. 
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TABLE 1 Dilution methods used to make up 1 µg synacthen dose and intra-method variability  
 
a6\QDFWKHQVWDUWLQJFRQFHQWUDWLRQZDVJP/:KHUHWKHPHWKRGVWDWHV³VDOLQH´DVRGLXPFKORULGHVROXWLRQZDVXVHG 
 
Method 
number Method summary 
Dilution 
factor 
Expected final 
concentration 
of synacthen 
Observed final 
concentration of 
synacthen (mean ± 
SD; n = 5) 
Intra-
method 
variability 
(% CV) 
Volume 
to 
deliver a 
1 µg 
dose 
Actual dose (µg) of 
synacthen 
deliverable in 
injected volume 
(mean ± SD; n = 5) 
1 1 mL of synacthena injected into a 1 litre bag of saline. 1000 250 ng/mL 195 ± 22 ng/mL 11.3 4 mL 0.78 ± 0.09 
2 
1 mL of synacthena transferred to 10 mL syringe containing 
9 mL of saline. 
1 mL of resultant solution transferred to 10 mL syringe 
containing 4 mL of saline. 
50 5 µg/mL 2.73 ± 0.79 µg/mL 28.9 0.2 mL 0.55 ± 0.16 
3 1 mL of synacthena injected into 250 mL bag of saline. 250 1000 ng/mL 522 ± 202 ng/mL 38.8 1 mL 0.52 ± 0.20 
4 
1 mL synacthena injected into 50 mL bag of saline. 1 mL of 
resultant solution transferred to 10 mL syringe containing 9 
mL of saline. 
500 500 ng/mL 391 ± 36 ng/mL 9.06 2 mL 0.78 ± 0.07 
5 
1 mL of synacthena injected into 50 mL bag of saline. 0.2 
mL of resultant solution transferred to 2.5 mL syringe 
containing 0.8 mL of saline. 
250 1000 ng/mL 559 ± 89 ng/mL 15.9 1 mL 0.56 ± 0.09 
6 1 mL of synacthen
a
 injected into 500 mL bag of 5% (w/v) 
dextrose. 500 500 ng/mL 407 ± 8 ng/mL 2.06 2 mL 0.81 ± 0.02 
7 
0.2 mL of synacthena transferred into 10 mL syringe 
containing 10 mL saline. 0.2 mL of resultant solution 
transferred to 2.5 mL syringe containing 0.8 mL of saline. 
250 1000 ng/mL 161 ± 39 ng/mL 24.7 1 mL 0.16 ± 0.04 
8 0.2 mL of synacthena injected into 50 mL bag of saline. 250 1000 ng/mL 632 ± 230 ng/mL 36.4 1 mL 0.63 ± 0.23 
9 0.1 mL of synacthena injected into 50 mL bag of saline. 500 500 ng/mL 181 ± 118 ng/mL 65.2 2 mL 0.36 ± 0.24 
10 0.5 mL synacthena of injected into 500 mL bag of saline. 1000 250 ng/mL 42 ± 47 ng/mL 109.6 4 mL 0.17 ± 0.19 
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TABLE 2 Percentage of adult and paediatric respondents using the different diagnostic 
tests for adrenal insufficiency 
 
 
 
 
Diagnostic test for adrenal 
insufficiency 
Percentage respondents using test 
Total 
(n = 766) 
Adult 
(n = 398) 
Paediatric 
(n = 345) 
Short cosyntropin test  97.8 97.7 98.8 
High-dose test  92 95.7 88.4 
Low-dose test  42.6 17.4 72.1 
Paired ACTH and serum cortisol 71 73.3 66.9 
Serum cortisol 76.4 67.3 87.5 
Salivary cortisol 20.2 25.2 14.2 
Insulin tolerance test 36 54.2 14.5 
Glucagon stimulation test 26.9 25.4 29.1 
Metyrapone test 4 5 2.9 
Clonidine stimulation test 2.6 1.5 3.5 
Corticotrophin releasing hormone test 1.9 1.8 2 
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Figure 1 
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Figure 2 
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Supporting Information 
 
Diagnostic Tests for Adrenal Insufficiency Survey 
 
 
1. In which country do you work?       
 
 
2. Which endocrine patient group do you work with?  
 
Drop down box:  Children/adolescents only 
   Mainly children/adolescents but some adults 
   Both children/adolescents AND adults 
   Mainly adults but some children/adolescents 
   Adults ONLY 
   Other (specify/add comments in the text box provided) 
 
   
3. Which tests do you use to assess hypothalamic-pituitary-adrenal (HPA) axis hypofunction?  
 Please select all that apply.  
 
  Early morning serum cortisol  
  Random serum cortisol  
  Paired ACTH and serum cortisol  
  Salivary cortisol  
  Insulin tolerance test 
  Standard-dose (short) Synacthen (Cosyntropin, Cortrosyn) test (250 mcg)  
  Low-dose (short) Synacthen (Cosyntropin, Cortrosyn) test (e.g. 1 mcg)  
  Glucagon stimulation test  
  Metyrapone test  
  Clonidine stimulation test  
  Other (please specify)            
 
 
4. We want to know what makes people choose between the standard-dose and low-dose (short) 
Synacthen (Cosyntropin, Cortrosyn) test. 
Dear Endocrinologist/Endocrine Specialist Nurse/ Paediatric Endocrine Society/ The Endocrine Society/ ESA/ 
ESE/SfE/ESPE member, 
 
We are surveying clinical approaches to diagnosing adrenal insufficiency, in particular the (short) Synacthen test 
(Cosyntropin, Cortrosyn, ACTH test, tetracosactide), within endocrinology departments (adult and paediatric) via the 
membership of Paediatric Endocrine Society, The Endocrine Society, Endocrine Society of Australia, European Society of 
Endocrinology, Society for Endocrinology and European Society of Paediatric Endocrinology. 
 
The different testing strategies for the HPA-axis, in particular the use of different doses of Synacthen, are controversial and 
this is the first survey to gather such information worldwide.   
 
We would be grateful if you would take a few minutes to complete this very short questionnaire.  
 
Thank you for your time. 
 
 Alex Cross, Charlotte Elder, Neil Wright, Nils Krone, Richard Ross. 
 University of Sheffield/Sheffield Children's Hospital, UK. 
 
If you have any problems completing this document, please contact Alex Cross on 
ascross1@sheffield.ac.uk 
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If you have indicated that you use the Synacthen test (standard-dose AND/ OR low-dose), please 
detail in which clinical scenarios/situations you would use each test, in preference to the other 
test. 
 
Standard-dose (short) Synacthen (Cosyntropin, Cortrosyn) test (250 mcg)       
 
Low-dose (short) Synacthen (Cosyntropin, Cortrosyn) test (e.g. 1 mcg)        
 
Any other comments        
 
5. In the assessment of adrenal insufficiency, if you use the STANDARD-DOSE (250 mcg) form of 
the (short) Synacthen (Cosyntropin, Cortrosyn) test, which route(s) do you most commonly 
administer it?  Please select all that apply.  
  Intravenous (IV)    
  Intramuscular (IM)  
  Subcutaneous (SC)  
 
6. In the assessment of adrenal insufficiency, if you use the LOW-DOSE form of the (short) 
Synacthen (Cosyntropin, Cortrosyn) test, what DOSE do you use?        
 
7. If you use the STANDARD-DOSE 
(short) Synacthen (Cosyntropin, 
Cortrosyn) test (250 mcg), at what times 
do you take your cortisol samples? 
 
Please select all that apply 
 
 I do not use the STANDARD-DOSE 
Synacthen test 
 0 minutes 
 10 minutes 
 20 minutes 
 30 minutes 
 60 minutes 
 90 minutes 
 Other time(s)  
(please specify)       
8. If you use the LOW-DOSE (short) 
Synacthen (Cosyntropin, Cortrosyn) test 
(e.g. 1 mcg), at what times do you take 
your cortisol samples? 
 
Please select all that apply 
 
 I do not use the LOW-DOSE 
Synacthen test 
 0 minutes 
 10 minutes 
 20 minutes 
 30 minutes 
 60 minutes 
 90 minutes 
 Other time (s) 
(please specify)      
 
 
9.  Which assay(s) do you use to analyse your cortisol samples? If you do not know, please write 
³GRQ¶WNQRZ´LQWKHWH[WER[SURYLGHG        
 
 
10. How have your diagnostic cut offs for adrenal insufficiency been set?  
Drop down box:  Locally according to your specific assay 
   Locally- other (please specify below) 
   From textbook definitions (please specify below) 
   From another source (please specify below) 
   'RQ¶WNQRZ  
 
Please add further information here       
 
 
11. If/when interpreting the results of a (short) Synacthen (Cosyntropin, Cortrosyn) test (standard or 
low-dose), which of the following diagnostic criteria do you use? 
Drop down box:  I do not use the Synacthen (Cosyntropin, Cortrosyn) test 
   Peak cortisol ONLY 
   Rise from baseline (absolute or fold increase) ONLY 
   Both peak cortisol and rise from baseline 
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 12.  If you use the STANDARD-DOSE (short) Synacthen (Cosyntropin, Cortrosyn) test, what cut off 
for normal do you use?  
 Please select all that apply, e.g. peak threshold AND rise from baseline increment. 
 
  I do not use the STANDARD-dose Synacthen test 
 
 Peak cortisol >400 nmol/l   
  (>14.5 µg/dL) 
 Peak cortisol >450 nmol/l   
  (>16.3 µg/dL) 
 Peak cortisol >500 nmol/l     
  (>18 µg/dL) 
  Peak cortisol >550 nmol/l    
  (>20 µg/dL) 
  Peak cortisol >580 nmol/l    
  (>21 µg/dL) 
 
  Rise from baseline  
>150 nmol/l (>5.4 µg/dL) 
  Rise from baseline  
> 200 nmol/l (>7.2 µg/dL) 
 
  Other concentration  
(please specify)       
 
 
 13.  If you use the LOW DOSE (short) Synacthen (Cosyntropin, Cortrosyn) test, what cut off for 
normal do you use? 
 Please select all that apply, e.g. peak threshold AND rise from baseline increment. 
 
  I do not use the LOW-dose Synacthen test 
 Peak cortisol >400 nmol/l   
  (>14.5 µg/dL) 
 Peak cortisol >450 nmol/l   
  (>16.3 µg/dL) 
 Peak cortisol >500 nmol/l     
  (>18 µg/dL) 
  Peak cortisol >550 nmol/l    
  (>20 µg/dL) 
  Peak cortisol >580 nmol/l    
  (>21 µg/dL) 
 
 
  Rise from baseline  
>150 nmol/l (>5.4 µg/dL) 
  Rise from baseline  
> 200 nmol/l (>7.2 µg/dL) 
 
  Other concentration  
(please specify)
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